Analyst Note: Forest Labs
Analyst Note: Forest Labs
Analyst Savant Ahmed downgraded Forest to \"Underweight\" from \"Neutral,\" but increased the price target on the stock to $45 from $43. Ahmed estimates a fair value range of $40 to $50 per share.
Health calendar and support groups
"Nutrition After Cancer . " Class. Noon-1:30 p.m. Cordelia Knott Center for Wellness, 230 S. Main St., Johnson Hall, Suite 100, Orange. 714-541-9355, Ext. 3337.
Sosei Announces Start of Phase II Trial of AD 337 in Fibromyalgia Syndrome
Sosei Group Corporation , the biopharmaceutical company, today announces that AD 337, a novel enantiomer of an approved centrally acting non-opioid analgesic, has entered a Phase II proof of principle trial for the treatment of fibromyalgia syndrome .
Technorati Tags:
fibromylagia treatment